Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Systemic lupus erythematosus
•
Complement system
How have you utilized commercial lab "SLE Monitoring Profiles" that include C3a and C4a components?
What are the limitations, usefulness, and caveats of this testing?
Related Questions
How do you approach a patient with high titer ANA and a new diagnosis of ITP, but no other signs or symptoms suggestive of active rheumatologic disease?
What is the clinical significance of a low titer RNP, negative Sm, but Sm/RNP that is very high titer?
What is your approach to the management of shrinking lung syndrome in SLE?
Should patients starting cyclophosphamide be screened routinely for latent tuberculosis (TB)?
How do you approach new-onset idiopathic intracranial hypertension (IIH) with someone who has history of systemic lupus erythematosus?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
Can lupus anticoagulant be positive despite a normal aPTT?
How soon would you repeat PET/CT in a patient with cardiac sarcoid after starting treatment with infliximab?
What are some practical tips in distinguishing between metabolic bone disease due to chronic kidney disease and osteoporosis?
In patients with possible early SLE or undifferentiated disease can multiomics be used to help predict what disease phenotype they will develop?